Hot Features
Premium
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - |
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Vallon Pharmaceuticals Inc | VLON | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 0.40 | 19:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 0.40 |
| Trades | Shares Traded | Average Volume |
|---|---|---|
| 0 | 0 | - |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| - | 0 | US$ 0.40 | USD |
Vallon Pharmaceuticals Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 1.3M | 3.25M | - | 0 | -13.04M | -4.02 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Vallon Pharmaceuticals News
| Date | Time | Source | News Article |
|---|---|---|---|
| 4/01/2024 | 08:13 | Edgar (US Regulatory) | Form 8-K - Current report |
| 3/28/2024 | 15:45 | Edgar (US Regulatory) | Form 424B3 - Prospectus [Rule 424(b)(3)] |
| 3/28/2024 | 15:42 | Edgar (US Regulatory) | Form 424B3 - Prospectus [Rule 424(b)(3)] |
| 2/02/2024 | 15:25 | Edgar (US Regulatory) | Form 424B3 - Prospectus [Rule 424(b)(3)] |
| 2/02/2024 | 15:23 | Edgar (US Regulatory) | Form 8-K - Current report |
| 2/02/2024 | 15:21 | Edgar (US Regulatory) | Form 424B4 - Prospectus [Rule 424(b)(4)] |
| 2/01/2024 | 23:15 | Edgar (US Regulatory) | Form EFFECT - Notice of Effectiveness |
| 1/30/2024 | 07:13 | Edgar (US Regulatory) | Form 424B3 - Prospectus [Rule 424(b)(3)] |
| 1/30/2024 | 07:12 | Edgar (US Regulatory) | Form 8-K - Current report |
| 1/19/2024 | 15:16 | Edgar (US Regulatory) | Form 424B3 - Prospectus [Rule 424(b)(3)] |
| 1/19/2024 | 15:15 | Edgar (US Regulatory) | Form 8-K - Current report |
| 1/16/2024 | 07:45 | Edgar (US Regulatory) | Form 8-K - Current report |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical VLON Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 1 Month | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 3 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 6 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 1 Year | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 3 Years | 4.24 | 10.36 | 0.2054 | 1.45 | 1,864,808 | -3.84 | -90.57% |
| 5 Years | 8.27 | 10.36 | 0.2054 | 1.47 | 1,679,329 | -7.87 | -95.16% |
Vallon Pharmaceuticals Description
| Vallon Pharmaceuticals Inc is a biopharmaceutical company, which focuses on the development and commercialization of proprietary biopharmaceutical products. The company develops prescription drugs for central nervous system disorders. Its product ADAIR, a proprietary, abuse-deterrent oral formulation of immediate-release dextroamphetamine for the treatment of attention-deficit/hyperactivity disorder, and narcolepsy. |
